ReviewDrug discovery today2017
Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics.
Review in Drug discovery today, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- A magnetic resonance imaging-guided drug delivery system for premetastatic niche theranostics and colorectal cancer liver metastasis intervention.Journal of nanobiotechnology · 2026Article
- Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications.Advanced healthcare materials · 2025Review
- Iron oxide nanoparticles empowering melanoma therapy: advances in multifunctional platform research.Frontiers in bioengineering and biotechnology · 2025Review
- Nanomedicines: Emerging Platforms in Smart Chemotherapy Treatment-A Recent Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer.Biomedical microdevices · 2024Review
- Dual conjugation of magnetic nanoparticles with antibodies and siRNA for cell-specific gene silencing in vascular cells.Frontiers in drug delivery · 2024Article
- Utilization of nanomaterials in MRI contrast agents and their role in therapy guided by imaging.Frontiers in bioengineering and biotechnology · 2024Review
- Bovine Lactoferrin-Loaded Plasmonic Magnetoliposomes for Antifungal Therapeutic Applications.Pharmaceutics · 2023Article
- A Hyperbranched Polyol Process for Designing and Manufacturing Nontoxic Cobalt Nanocomposite.Polymers · 2023Article
- Nanotechnology-Aided Advancement in Combating the Cancer Metastasis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Dual-Peak Lorentzian CEST MRI for antiretroviral drug brain distribution.NeuroImmune pharmacology and therapeutics · 2023Article
- Amplifying cancer treatment: advances in tumor immunotherapy and nanoparticle-based hyperthermia.Frontiers in immunology · 2023Review
- Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia.Frontiers in pharmacology · 2023Review
- Nanomedicine approaches to reduce cytokine storms in severe infections.Drug discovery today · 2022Review
- Magneto-Orientation of Magnetic Double Stacks for Patterned Anisotropic Hydrogels with Multiple Responses and Modulable Motions.Angewandte Chemie (International ed. in English) · 2022Article
- Nanotechnology-aided advancement in the combating of cancer metastasis.Cancer metastasis reviews · 2022Review
- Advances in Electrospun Hybrid Nanofibers for Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- Synthesis and Characterization of Magnetic Composite Theragnostics by Nano Spray Drying.Materials (Basel, Switzerland) · 2022Article
- Electrospun hybrid nanofibers: Fabrication, characterization, and biomedical applications.Frontiers in bioengineering and biotechnology · 2022Review
- Dual-Target Multifunctional Superparamagnetic Cationic Nanoliposomes for Multimodal Imaging-Guided Synergistic Photothermal/Photodynamic Therapy of Retinoblastoma.International journal of nanomedicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Superparamagnetic iron oxide (SPIO) nanoparticles have been intensively studied for the development of contrast agents in MRI. First-generation SPIO nanoparticles had diagnostic capabilities only, whereas a new generation of SPIO nanoparticle has multifunctional characteristics for combined therapeutic and diagnostic applications. These theranostic nanoparticles hold great potential for image-guided cancer therapies. In particular, polymer-coated theranostic SPIO nanoparticles have enjoyed increasing attention as a result of good biocompatibility, biodegradability and versatile functionality endowed by polymeric matrices. This review provides an overview of recently developed polymer-coated multifunctional SPIO nanoparticles for cancer theranostics and discusses current challenges and future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.